metastatic squamous neck cancer with occult primary squamous cell carcinoma
Showing 1 - 25 of >10,000
Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx
Active, not recruiting
- Head and Neck Squamous Cell Carcinoma
- +14 more
- Laboratory Biomarker Analysis
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 11, 2022
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With
Completed
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
- +35 more
- PI3K inhibitor BKM120
- cetuximab
-
Chicago, IllinoisUniversity of Chicago Comprehensive Cancer Center
Sep 14, 2021
Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell
Active, not recruiting
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
- +29 more
- Cytology specimen
- Laboratory biomarker analysis
-
Philadelphia, PennsylvaniaThomas Jefferson University
Aug 31, 2021
Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma Trial in Portland (GB1211, Pembrolizumab, Placebo)
Not yet recruiting
- Metastatic Melanoma
- Head and Neck Squamous Cell Carcinoma
- GB1211
- +2 more
-
Portland, OregonProvidence Portland Medical Center
Jun 19, 2023
Regional Nodal Basins and Gene Expression Profiling in Primary
Not yet recruiting
- Cutaneous Squamous Cell Carcinoma of the Head and Neck
- Ultrasound
- 40-GEP
- (no location specified)
Jul 12, 2023
Prognostic Immune Biomarkers in HNSCC
Completed
- Head and Neck Cancer
- Squamous Cell Carcinoma
- Tumour immunoprofile evaluation
-
Ostrava, Moravian-Silesian Region, CzechiaUniversity Hospital Ostrava
Jul 3, 2023
Head and Neck Squamous Cell Carcinoma Trial (Carrilizumab, bevacizumab,capecitabine)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Carrilizumab, bevacizumab,capecitabine
- (no location specified)
Jul 20, 2023
Head and Neck Squamous Cell Carcinoma, Head Neck Cancer Trial (Tislelizumab, BGB-A425, LBL-007)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Head and Neck Cancer
- Tislelizumab
- +2 more
- (no location specified)
Jun 9, 2023
HLA-DR in Cell Cultures Isolated From Primary Squamous Cell
Active, not recruiting
- Squamous Cell Carcinoma of the Head and Neck
- Cancer
- cell culture
-
Roma, Lazio, ItalyFondazione Policlinico Universitario Gemelli, Irccs
Sep 11, 2023
Squamous Cell Carcinoma, Nonmelanoma Skin Cancer, Cutaneous Squamous Cell Carcinoma Trial in Indianapolis (sentinel lymph node
Recruiting
- Squamous Cell Carcinoma
- +2 more
- sentinel lymph node biopsy (SLNB)
-
Indianapolis, IndianaIndiana University Melvin & Bren Simon Cancer Center
Nov 15, 2022
Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma Trial (Ficlatuzumab,
Not yet recruiting
- Metastatic Head-and-neck Squamous-cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Ficlatuzumab
- +2 more
- (no location specified)
Sep 26, 2023
Head and Neck Squamous Cell Carcinoma Trial (Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Zanzalintinib
- +2 more
- (no location specified)
Oct 9, 2023
Sinonasal Cancer, Squamous NSCLC, Lung Cancer Trial run by the National Cancer Institute (NCI) (pembrolizumab, valemetostat)
Not yet recruiting
- Sinonasal Cancer
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jun 5, 2023
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous
Active, not recruiting
- Recurrent Head and Neck Squamous Cell Carcinoma
- +3 more
- 200 mg Pembrolizumab
- +2 more
-
Miami, Florida
- +6 more
Jan 9, 2023
Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- +2 more
- Panitumumab
- +4 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Feb 16, 2023
Head Neck, Squamous Cell Carcinoma of Head and Neck Trial in Houston (Pembrolizumab, Magrolimab, cetuximab)
Not yet recruiting
- Head Neck
- Squamous Cell Carcinoma of Head and Neck
- Pembrolizumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Sep 14, 2023
Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity
Active, not recruiting
- Squamous Cell Carcinoma of the Oropharynx
- +7 more
-
Tampa, Florida
- +2 more
Dec 30, 2022
Head Neck Cancer, Squamous Cell Carcinoma of the Head and Neck Trial in La Jolla (Ibrutinib 560mg PO daily (Imbruvica),
Active, not recruiting
- Head and Neck Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Ibrutinib 560mg PO daily (Imbruvica)
- +2 more
-
La Jolla, CaliforniaUCSD Moores Cancer Center
Jan 11, 2023
Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint
Not yet recruiting
- Recurrent Head and Neck Cancer
- +5 more
-
Saint Louis, MissouriWashington University School of Medicine
Jul 30, 2023
Head and Neck Squamous Cell Carcinoma, Locally Advanced Operable Trial in Guangzhou (Cadonilimab, Docetaxel, Cisplatin)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Locally Advanced Operable
- Cadonilimab
- +2 more
-
Guangzhou, Guangdong, China
- +1 more
Sep 4, 2023
Locally Advanced Head and Neck Squamous Cell Carcinoma Trial (Toripalimab)
Not yet recruiting
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- (no location specified)
Mar 20, 2023
Head Neck Cancer Trial in Charleston (Pembrolizumab, Clopidogrel, acetylsalicylic acid)
Recruiting
- Head and Neck Cancer
- Pembrolizumab
- +2 more
-
Charleston, South CarolinaMedical University of South Carolina
Dec 22, 2022
Cancer of Unknown Primary Site, Unknown Primary Cancer, Unknown Primary, Squamous Cell Carcinoma Trial in Copenhagen, Ã…rhus
Recruiting
- Cancer of Unknown Primary Site
- +2 more
- Transoral Ultrasound
-
Copenhagen, Denmark
- +1 more
May 2, 2023